Apyx Medical Corp. (APYX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apyx Medical Corporation Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Introduces Fiscal Year 2019 Outlook
March 13, 2019 4:05 PM EDTAdvanced Energy Sales increase 40% year-over-year in Q4 and increase 71% year-over-year in FY18
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its fourth quarter and fiscal year ended December31, 2018.
Fiscal Year 2018 Financial Summary:
2018 total revenue from continuing operations of approximately $16.7 million, up 63% year-over-year. Advanced Energy revenue of $13.1... More